The “Ozempic phenomenon” has captured widespread attention. Celebrity endorsements and viral TikTok transformations continue to fuel the idea that this diabetes medication is a rapid slimming solution. The hashtag #OzempicWeightLoss has drawn hundreds of millions of views, and discussions about which stars are using it dominate entertainment headlines.

In recent years, the popularity of semaglutide-based medications such as Ozempic, Wegovy and tirzepatide (sold as Mounjaro) has skyrocketed around the world, leading to shortages, off-label prescribing, and even a black market. In Australia, Ozempic is only approved for the management of type 2 diabetes,.

At the beginning of the hype in 2023, demand surged so dramatically that it caused nationwide shortages, leaving many people with type 2 diabetes struggling to access their essential treatment. While supply has become more stable, demand remains strong and discussions about whether weight-loss medications should be subsidised on the Pharmaceutical Benefits Scheme (PBS) are gaining momentum. At the same time, lawsuits have begun mounting in the U.S., with thousands of patients claiming serious side effects such as gastroparesis were not adequately disclosed by manufacturers.

Against this backdrop, it is important to step back from the headlines and examine what Ozempic actually does, who it is for, and why HIF recommends speaking to your GP or specialist before starting any prescription treatment.